Protein Network Analysis Identifies Changes in the Level of Proteins Involved in Platelet Degranulation, Proteolysis and Cholesterol Metabolism Pathways in AECOPD Patients

References

• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582. doi:10.1164/rccm.201701-0218PP.
   PubMed Web of Science ®Google Scholar
• Sethi S, Evans N, Grant BJ, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;347(7):465–471. doi:10.1056/NEJMoa012561.
   PubMed Web of Science ®Google Scholar
• Lieberman D, Lieberman D, Ben-Yaakov M, et al. Infectious etiologies in acute exacerbation of COPD. Diagnostic Microbiol Infect Dis. 2001;40(3):95–102. doi:10.1016/S0732-8893(01)00255-3.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA. Role of viruses in exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004;1(2):115–120. doi:10.1513/pats.2306030.
   PubMedGoogle Scholar
• Ko FW, Hui DS. Air pollution and chronic obstructive pulmonary disease. Respirology. 2012;17(3):395–401. doi:10.1111/j.1440-1843.2011.02112.x.
   PubMed Web of Science ®Google Scholar
• Sapey E, Stockley R. COPD exacerbations·2: Aetiology. Thorax 2006;61(3):250–258. doi:10.1136/thx.2005.041822.
   PubMed Web of Science ®Google Scholar
• Terracciano R, Pelaia G, Preiano M, et al. Asthma and COPD proteomics: current approaches and future directions. Prot Clin Appl. 2015;9(1–2):203–220. doi:10.1002/prca.201400099.
   PubMed Web of Science ®Google Scholar
• Lee EJ, In KH, Kim JH, et al. Proteomic analysis in lung tissue of smokers and COPD patients. Chest 2009;135(2):344–352. doi:10.1378/chest.08-1583.
   PubMed Web of Science ®Google Scholar
• Ohlmeier S, Vuolanto M, Toljamo T, et al. Proteomics of human lung tissue identifies surfactant protein A as a marker of chronic obstructive pulmonary disease. J Proteome Res. 2008;7(12):5125–5132. doi:10.1021/pr800423x.
   PubMed Web of Science ®Google Scholar
• Merkel D, Rist W, Seither P, et al. Proteomic study of human bronchoalveolar lavage fluids from smokers with chronic obstructive pulmonary disease by combining surface-enhanced laser desorption/ionization-mass spectrometry profiling with mass spectrometric protein identification. Proteomics. 2005;5(11):2972–2980. doi:10.1002/pmic.200401180.
   PubMed Web of Science ®Google Scholar
• Nicholas BL, Skipp P, Barton S, et al. Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181(10):1049–1060. doi:10.1164/rccm.200906-0857OC.
   PubMed Web of Science ®Google Scholar
• Bringans SD, Ito J, Stoll T, et al. Comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease. EuPA Open Proteom. 2017;14:1–10. doi:10.1016/j.euprot.2016.12.001.
   PubMedGoogle Scholar
• Karadag F, Kirdar S, Karul AB, et al. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Eur J Intern Med. 2008;19(2):104–108. doi:10.1016/j.ejim.2007.04.026.
   PubMed Web of Science ®Google Scholar
• Dieplinger H, Dieplinger B. Afamin–A pleiotropic glycoprotein involved in various disease states. Clin Chim Acta. 2015;446:105–110. doi:10.1016/j.cca.2015.04.010.
   PubMed Web of Science ®Google Scholar
• Dieplinger B, Egger M, Gabriel C, et al. Analytical characterization and clinical evaluation of an enzyme-linked immunosorbent assay for measurement of afamin in human plasma. Clin Chim Acta. 2013;425:236–241. doi:10.1016/j.cca.2013.08.016.
   PubMed Web of Science ®Google Scholar
• Asherson RA, Cervera R. The antiphospholipid syndrome: multiple faces beyond the classical presentation. Autoimmun Rev. 2003;2(3):140–151. doi:10.1016/S1568-9972(02)00147-7.
   PubMed Web of Science ®Google Scholar
• Man SF, Xing L, Connett JE, et al. Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD? Eur Respir J. 2008;32(6):1451–1457. doi:10.1183/09031936.00153207.
   PubMed Web of Science ®Google Scholar
• Janciauskiene S, Wrenger S, Immenschuh S, et al. The multifaceted effects of Alpha1-Antitrypsin on neutrophil functions. Front Pharmacol. 2018;9:341. doi:10.3389/fphar.2018.00341.
   PubMed Web of Science ®Google Scholar
• Paliogiannis P, Fois AG, Sotgia S, et al. Neutrophil to lymphocyte ratio and clinical outcomes in COPD: recent evidence and future perspectives. Eur Respir Rev. 2018;27(147):170113. doi:10.1183/16000617.0113-2017.
   PubMed Web of Science ®Google Scholar
• Lee KY, Feng PH, Ho SC, et al. Inter-alpha-trypsin inhibitor heavy chain 4: a novel biomarker for environmental exposure to particulate air pollution in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:831–841. doi:10.2147/COPD.S81611.
   PubMed Web of Science ®Google Scholar
• Mahley RW. Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. J Mol Med. 2016;94(7):739–746. doi:10.1007/s00109-016-1427-y.
   PubMed Web of Science ®Google Scholar
• Serna M, Giles JL, Morgan BP, et al. Structural basis of complement membrane attack complex formation. Nat Commun. 2016;7(1):10587. doi:10.1038/ncomms10587.
   PubMedGoogle Scholar
• Marc MM, Kristan SS, Rozman A, et al. Complement factor C5a in acute exacerbation of Chronic Obstructive Pulmonary Disease. Scand J Immunol. 2010;71(5):386–391. doi:10.1111/j.1365-3083.2010.02385.x.
   PubMed Web of Science ®Google Scholar
• Ha YJ, Kang EJ, Lee SW, et al. Usefulness of serum leucine-rich alpha-2 glycoprotein as a disease activity biomarker in patients with rheumatoid arthritis. J Korean Med Sci. 2014;29(9):1199–1204. doi:10.3346/jkms.2014.29.9.1199.
   PubMed Web of Science ®Google Scholar
• Honda H, Fujimoto M, Miyamoto S, et al. Sputum Leucine-Rich Alpha-2 glycoprotein as a marker of airway inflammation in asthma. PLoS One. 2016;11(9):e0162672. doi:10.1371/journal.pone.0162672.
   PubMed Web of Science ®Google Scholar
• Kunisaki KM, Dransfield MT, Anderson JA, et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events. A Post Hoc Cohort Analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med. 2018;198(1):51–57. doi:10.1164/rccm.201711-2239OC.
   PubMed Web of Science ®Google Scholar
• Papaioannou AI, Bartziokas K, Loukides S, et al. Cardiovascular comorbidities in hospitalised COPD patients: a determinant of future risk? Eur Respir J. 2015;46(3):846–849. doi:10.1183/09031936.00237014.
   PubMed Web of Science ®Google Scholar
• Leung JM, Chen V, Hollander Z, et al. COPD exacerbation biomarkers validated using multiple reaction monitoring mass spectrometry. PLoS One. 2016;11(8):e0161129. doi:10.1371/journal.pone.0161129.
   PubMed Web of Science ®Google Scholar
• Shi L, Zhu B, Xu M, et al. Selection of AECOPD-specific immunomodulatory biomarkers by integrating genomics and proteomics with clinical informatics. Cell Biol Toxicol. 2018;34(2):109–123. doi:10.1007/s10565-017-9405-x.
   PubMed Web of Science ®Google Scholar
• Chen H, Wang Y, Bai C, et al. Alterations of plasma inflammatory biomarkers in the healthy and chronic obstructive pulmonary disease patients with or without acute exacerbation. J Proteomics. 2012;75(10):2835–2843. doi:10.1016/j.jprot.2012.01.027.
   PubMed Web of Science ®Google Scholar